Compare Amylx Pharmaceuticals Inc (AMLX) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Teradyne, Inc. trades at $349 (market cap $56.29B). The key difference: Teradyne, Inc. is far larger — about 28.4× Amylx Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TER | |
|---|---|---|
Market Cap | $1.98B | $56.29B |
Sector | Health | Technology |
52-Week High | $18.70 | $483.84 |
52-Week Low | $7.64 | $90.15 |
Enterprise Value | $1.70B | $56.13B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Teradyne (TER) trades at $359.60, down 0.87% amid a bearish technical signal, though it remains supported by strong fundamentals including a 22.55% net income margin and consistent earnings beats. Recent news highlights AI-driven data center demand boosting revenue, with Q2 2026 EPS expected at $2.04. The company maintains robust profitability metrics like 28.75% ROE, but faces headwinds from negative net cash flow trends and elevated valuation ratios (P/E 66.72).
Outlook: TER's AI and robotics exposure offers growth potential, with a consensus price target of $453.60 implying 26% upside. Risks include semiconductor cycle volatility and high valuations. Analyst sentiment is bullish (64.5% buy ratings), but investors should monitor execution on Q2 earnings and cash flow improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
